FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

	dress of Reporting	•	2. Issuer Name and Ticker or Trading Symbol <u>Transcode Therapeutics, Inc.</u> [RNAZ]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Dudley Robert Michael			[]	X	Director	10% Owner			
(Last)	st) (First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/20/2023	x	Officer (give title below)	Other (specify below)			
C/O TRANS	CODE THERA	PEUTICS, INC.	00/20/2023		Chief Executive Officer				
6 LIBERTY SQUARE, #2382			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)				X	Form filed by One Re	eporting Person			
BOSTON	MA	02109			Form filed by More th Person	nan One Reporting			
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication						
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan the satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

			•	'		,				
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	, Transaction Code (Instr.		4. Securities Disposed Of		ed (A) or tr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	06/20/2023		Р		6,607	A	\$2.5498 ⁽¹⁾	70,262	D	
Common Stock	06/21/2023		Р		12,000	A	\$2.6515 ⁽²⁾	82,262	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

		(0191, pu	,	, .		,	•••••••			ounnoo	-7			
1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from \$2.54 to \$2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

2. Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from \$2.60 to \$2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

<u>/s/ Thomas A. Fitzgerald, as</u> <u>Attorney-in-Fact</u>	<u>06/22/2023</u>
	D .

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5